אומניק 0.4 ישראל - עברית - Ministry of Health

אומניק 0.4

cts ltd - tamsulosin hydrochloride - modified release capsules - tamsulosin hydrochloride 0.4 mg - treatment of functional symptoms of benign prostatic hyperplasia (bph).

אופלוקסצין טבע 200 מג ישראל - עברית - Ministry of Health

אופלוקסצין טבע 200 מג

abic ltd. - ofloxacin - טבליה - ofloxacin 200 mg - ofloxacin - ofloxacin - bacterial infections due to ofloxacin-susceptible microorganisms, such as:- acute, chronic, or recurrent lower respiratory tract infections (bronchitis) pneumonia (not for the treatment of first choice in pnemonia caused by pneumococci). - chronic and recurrent infections of the ear, nose, and throat. ofloxacin is in general not indicated for the treatment of acute tonsillitis caused by betahaemolytic streptococci. - infections of soft tissues and skin. - infections of the bones and joints. - abdominal infections including infections in the pelvis minor and bacterial enteritis. - infections of the kidney, urinary tract, and genital organs, gonorrhoea.prevention of infections due to ofloxacin-susceptible pathogens in patients with a significant reduction in resistance to infections (e.g. in neutropenic state).

זיאגן טבליות ישראל - עברית - Ministry of Health

זיאגן טבליות

glaxo smith kline (israel) ltd - abacavir as sulfate - טבליות מצופות פילם - abacavir as sulfate 300 mg - abacavir - abacavir - ziagen is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infected adults and children.

אדוראנט ישראל - עברית - Ministry of Health

אדוראנט

j-c health care ltd - rilpivirine as hydrochloride - טבליה - rilpivirine as hydrochloride 25 mg - rilpivirine - rilpivirine - edurant in combination with other antiretroviral agents for the treatment of hiv-1 infection in treatment-na?ve adult patients.

אוויפלרה ישראל - עברית - Ministry of Health

אוויפלרה

j-c health care ltd - emtricitabine; rilpivirine as hydrochloride; tenofovir disoproxil as fumarate - טבליות מצופות פילם - tenofovir disoproxil as fumarate 245 mg; rilpivirine as hydrochloride 25 mg; emtricitabine 200 mg - rilpivirine - rilpivirine - eviplera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) is indicated for use as a complete regimen for the treatment of hiv-1 infection in antiretroviral treatment-naive adults. this indication is based on week 48 safety and efficacy analyses from 2 randomized, double-blind, active controlled, phase 3 trials in treatment-naive subjects comparing rilpivirine to efavirenz . the following points should be considered when initiating therapy with eviplera: -more rilpivirine-treated subjects with hiv-1 rna greater than 100,000 copies/ml at the start of therapy experienced virologic failure compared to subjects with hiv-1 rna less than 100,000 copies/ml at the start of therapy. -the observed virologic failure rate in rilpivirine-treated subjects conferred a higher rate of overall treatment resistance and cross-resistance to the nnrti class compared to efavirenz . -more subjects treated with rilpivirine developed lamivudine/emtricitabine associated resistance compared to efavirenz. -eviplera is not recomme

אוויפלרה ישראל - עברית - Ministry of Health

אוויפלרה

j-c health care ltd - emtricitabine; rilpivirine as hydrochloride; tenofovir disoproxil as fumarate - טבליות מצופות פילם - tenofovir disoproxil as fumarate 245 mg; rilpivirine as hydrochloride 25 mg; emtricitabine 200 mg - rilpivirine - rilpivirine - eviplera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) is indicated for use as a complete regimen for the treatment of hiv-1 infection in antiretroviral treatment-naive adults. this indication is based on week 48 safety and efficacy analyses from 2 randomized, double-blind, active controlled, phase 3 trials in treatment-naive subjects comparing rilpivirine to efavirenz . the following points should be considered when initiating therapy with eviplera: -more rilpivirine-treated subjects with hiv-1 rna greater than 100,000 copies/ml at the start of therapy experienced virologic failure compared to subjects with hiv-1 rna less than 100,000 copies/ml at the start of therapy. -the observed virologic failure rate in rilpivirine-treated subjects conferred a higher rate of overall treatment resistance and cross-resistance to the nnrti class compared to efavirenz . -more subjects treated with rilpivirine developed lamivudine/emtricitabine associated resistance compared to efavirenz. -eviplera is not recomme

אינלייטה 1 מג ישראל - עברית - Ministry of Health

אינלייטה 1 מג

pfizer pharmaceuticals israel ltd - axitinib - טבליות מצופות פילם - axitinib 1 mg - axitinib - axitinib - for the treatment of advanced renal cell carcinoma (rcc) after failure of one prior systemic therapy.

אינלייטה 5 מג ישראל - עברית - Ministry of Health

אינלייטה 5 מג

pfizer pharmaceuticals israel ltd - axitinib - טבליות מצופות פילם - axitinib 5 mg - axitinib - axitinib - for the treatment of advanced renal cell carcinoma (rcc) after failure of one prior systemic therapy.

אתופן XL 600 ישראל - עברית - Ministry of Health

אתופן xl 600

taro pharmaceutical industries ltd - etodolac - טבליות עם שחרור נרחב - etodolac 600 mg - etodolac - etodolac - for the management of signs and symptoms of osteoarthritis and rheumatoid arthritis.

אתופן  XL 500 ישראל - עברית - Ministry of Health

אתופן xl 500

taro pharmaceutical industries ltd - etodolac - טבליות עם שחרור נרחב - etodolac 500 mg - etodolac - etodolac - for the management of signs and symptoms of osteoarthrities and rheumatoid arthritis.